The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age
- 14 September 2010
- journal article
- research article
- Published by Elsevier in Contraception
- Vol. 83 (3), 218-222
- https://doi.org/10.1016/j.contraception.2010.07.027
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraceptionContraception, 2007
- Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuationContraception, 2006
- WHO statement on hormonal contraception and bone healthContraception, 2006
- Ibandronate: The Evolution of a Once-a-Month Oral Therapy for Postmenopausal OsteoporosisJournal of Clinical Densitometry, 2006
- Progestogen-only contraception and bone mineral density: a systematic reviewContraception, 2006
- Depo-Provera's black box: time to reconsider?Contraception, 2005
- Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraceptionContraception, 2002
- Forearm bone density in users of Depo-Provera as a contraceptive methodFertility and Sterility, 1999
- Long-term depot-medroxyprogesterone acetate and bone mineral densityContraception, 1999
- Bone density among long-term users of medroxyprogesterone acetate as a contraceptiveContraception, 1998